Earlier, SMBC Nikko analyst David Hoang initiated coverage of Arrowhead with an Outperform rating and $80 price target.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on ARWR:
- Arrowhead Soars after New Asthma Drug Tests
- Arrowhead announces interim results of ARO-RAGE study
- Biotech Alert: Searches spiking for these stocks today
- SVB Securities Likes Arrowhead Pharmaceuticals; Investors Join In
- Arrowhead upgraded to Outperform from Market Perform at SVB Securities
Questions or Comments about the article? Write to editor@tipranks.com